{"id":2320,"date":"2024-10-08T13:04:20","date_gmt":"2024-10-08T11:04:20","guid":{"rendered":"https:\/\/www.ipsen.com\/germany\/?post_type=press_release&#038;p=2320"},"modified":"2024-10-10T13:09:39","modified_gmt":"2024-10-10T11:09:39","slug":"ipsen-erhalt-eu-zulassung-fur-iqirvo-elafibranor-als-erste-neue-therapie-fur-primar-biliare-cholangitis-pbc-seit-fast-einem-jahrzehnt","status":"publish","type":"press_release","link":"https:\/\/www.ipsen.com\/germany\/press-releases\/ipsen-erhalt-eu-zulassung-fur-iqirvo-elafibranor-als-erste-neue-therapie-fur-primar-biliare-cholangitis-pbc-seit-fast-einem-jahrzehnt\/","title":{"rendered":"Ipsen erh\u00e4lt EU-Zulassung f\u00fcr IQIRVO\u00ae (Elafibranor) als erste neue Therapie f\u00fcr prim\u00e4r bili\u00e4re Cholangitis (PBC) seit fast einem Jahrzehnt"},"content":{"rendered":"","protected":false},"excerpt":{"rendered":"","protected":false},"author":9,"template":"","categories":[30],"tags":[],"class_list":["post-2320","press_release","type-press_release","status-publish","has-post-thumbnail","hentry","category-seltene-erkrankungen","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Ipsen erh\u00e4lt EU-Zulassung f\u00fcr IQIRVO\u00ae (Elafibranor) als erste neue Therapie f\u00fcr prim\u00e4r bili\u00e4re Cholangitis (PBC) seit fast einem Jahrzehnt - Germany<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ipsen.com\/germany\/press-releases\/ipsen-erhalt-eu-zulassung-fur-iqirvo-elafibranor-als-erste-neue-therapie-fur-primar-biliare-cholangitis-pbc-seit-fast-einem-jahrzehnt\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ipsen erh\u00e4lt EU-Zulassung f\u00fcr IQIRVO\u00ae (Elafibranor) als erste neue Therapie f\u00fcr prim\u00e4r bili\u00e4re Cholangitis (PBC) seit fast einem Jahrzehnt - Germany\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ipsen.com\/germany\/press-releases\/ipsen-erhalt-eu-zulassung-fur-iqirvo-elafibranor-als-erste-neue-therapie-fur-primar-biliare-cholangitis-pbc-seit-fast-einem-jahrzehnt\/\" \/>\n<meta property=\"og:site_name\" content=\"Germany\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-10T11:09:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/6\/2023\/12\/06080352\/PR-final.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"856\" \/>\n\t<meta property=\"og:image:height\" content=\"446\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.ipsen.com\/germany\/press-releases\/ipsen-erhalt-eu-zulassung-fur-iqirvo-elafibranor-als-erste-neue-therapie-fur-primar-biliare-cholangitis-pbc-seit-fast-einem-jahrzehnt\/\",\"url\":\"https:\/\/www.ipsen.com\/germany\/press-releases\/ipsen-erhalt-eu-zulassung-fur-iqirvo-elafibranor-als-erste-neue-therapie-fur-primar-biliare-cholangitis-pbc-seit-fast-einem-jahrzehnt\/\",\"name\":\"Ipsen erh\u00e4lt EU-Zulassung f\u00fcr IQIRVO\u00ae (Elafibranor) als erste neue Therapie f\u00fcr prim\u00e4r bili\u00e4re Cholangitis (PBC) seit fast einem Jahrzehnt - Germany\",\"isPartOf\":{\"@id\":\"https:\/\/www.ipsen.com\/germany\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.ipsen.com\/germany\/press-releases\/ipsen-erhalt-eu-zulassung-fur-iqirvo-elafibranor-als-erste-neue-therapie-fur-primar-biliare-cholangitis-pbc-seit-fast-einem-jahrzehnt\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/germany\/press-releases\/ipsen-erhalt-eu-zulassung-fur-iqirvo-elafibranor-als-erste-neue-therapie-fur-primar-biliare-cholangitis-pbc-seit-fast-einem-jahrzehnt\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/6\/2023\/12\/06080352\/PR-final.jpg\",\"datePublished\":\"2024-10-08T11:04:20+00:00\",\"dateModified\":\"2024-10-10T11:09:39+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.ipsen.com\/germany\/press-releases\/ipsen-erhalt-eu-zulassung-fur-iqirvo-elafibranor-als-erste-neue-therapie-fur-primar-biliare-cholangitis-pbc-seit-fast-einem-jahrzehnt\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.ipsen.com\/germany\/press-releases\/ipsen-erhalt-eu-zulassung-fur-iqirvo-elafibranor-als-erste-neue-therapie-fur-primar-biliare-cholangitis-pbc-seit-fast-einem-jahrzehnt\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\/\/www.ipsen.com\/germany\/press-releases\/ipsen-erhalt-eu-zulassung-fur-iqirvo-elafibranor-als-erste-neue-therapie-fur-primar-biliare-cholangitis-pbc-seit-fast-einem-jahrzehnt\/#primaryimage\",\"url\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/6\/2023\/12\/06080352\/PR-final.jpg\",\"contentUrl\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/6\/2023\/12\/06080352\/PR-final.jpg\",\"width\":856,\"height\":446},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.ipsen.com\/germany\/press-releases\/ipsen-erhalt-eu-zulassung-fur-iqirvo-elafibranor-als-erste-neue-therapie-fur-primar-biliare-cholangitis-pbc-seit-fast-einem-jahrzehnt\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.ipsen.com\/germany\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ipsen erh\u00e4lt EU-Zulassung f\u00fcr IQIRVO\u00ae (Elafibranor) als erste neue Therapie f\u00fcr prim\u00e4r bili\u00e4re Cholangitis (PBC) seit fast einem Jahrzehnt\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.ipsen.com\/germany\/#website\",\"url\":\"https:\/\/www.ipsen.com\/germany\/\",\"name\":\"Germany\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.ipsen.com\/germany\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.ipsen.com\/germany\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"de\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.ipsen.com\/germany\/#organization\",\"name\":\"Germany\",\"url\":\"https:\/\/www.ipsen.com\/germany\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\/\/www.ipsen.com\/germany\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/6\/2023\/12\/07165742\/Latest_Ipsen-logo_168x48.svg\",\"contentUrl\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/6\/2023\/12\/07165742\/Latest_Ipsen-logo_168x48.svg\",\"caption\":\"Germany\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/germany\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ipsen erh\u00e4lt EU-Zulassung f\u00fcr IQIRVO\u00ae (Elafibranor) als erste neue Therapie f\u00fcr prim\u00e4r bili\u00e4re Cholangitis (PBC) seit fast einem Jahrzehnt - Germany","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ipsen.com\/germany\/press-releases\/ipsen-erhalt-eu-zulassung-fur-iqirvo-elafibranor-als-erste-neue-therapie-fur-primar-biliare-cholangitis-pbc-seit-fast-einem-jahrzehnt\/","og_locale":"de_DE","og_type":"article","og_title":"Ipsen erh\u00e4lt EU-Zulassung f\u00fcr IQIRVO\u00ae (Elafibranor) als erste neue Therapie f\u00fcr prim\u00e4r bili\u00e4re Cholangitis (PBC) seit fast einem Jahrzehnt - Germany","og_url":"https:\/\/www.ipsen.com\/germany\/press-releases\/ipsen-erhalt-eu-zulassung-fur-iqirvo-elafibranor-als-erste-neue-therapie-fur-primar-biliare-cholangitis-pbc-seit-fast-einem-jahrzehnt\/","og_site_name":"Germany","article_modified_time":"2024-10-10T11:09:39+00:00","og_image":[{"width":856,"height":446,"url":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/6\/2023\/12\/06080352\/PR-final.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ipsen.com\/germany\/press-releases\/ipsen-erhalt-eu-zulassung-fur-iqirvo-elafibranor-als-erste-neue-therapie-fur-primar-biliare-cholangitis-pbc-seit-fast-einem-jahrzehnt\/","url":"https:\/\/www.ipsen.com\/germany\/press-releases\/ipsen-erhalt-eu-zulassung-fur-iqirvo-elafibranor-als-erste-neue-therapie-fur-primar-biliare-cholangitis-pbc-seit-fast-einem-jahrzehnt\/","name":"Ipsen erh\u00e4lt EU-Zulassung f\u00fcr IQIRVO\u00ae (Elafibranor) als erste neue Therapie f\u00fcr prim\u00e4r bili\u00e4re Cholangitis (PBC) seit fast einem Jahrzehnt - Germany","isPartOf":{"@id":"https:\/\/www.ipsen.com\/germany\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.ipsen.com\/germany\/press-releases\/ipsen-erhalt-eu-zulassung-fur-iqirvo-elafibranor-als-erste-neue-therapie-fur-primar-biliare-cholangitis-pbc-seit-fast-einem-jahrzehnt\/#primaryimage"},"image":{"@id":"https:\/\/www.ipsen.com\/germany\/press-releases\/ipsen-erhalt-eu-zulassung-fur-iqirvo-elafibranor-als-erste-neue-therapie-fur-primar-biliare-cholangitis-pbc-seit-fast-einem-jahrzehnt\/#primaryimage"},"thumbnailUrl":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/6\/2023\/12\/06080352\/PR-final.jpg","datePublished":"2024-10-08T11:04:20+00:00","dateModified":"2024-10-10T11:09:39+00:00","breadcrumb":{"@id":"https:\/\/www.ipsen.com\/germany\/press-releases\/ipsen-erhalt-eu-zulassung-fur-iqirvo-elafibranor-als-erste-neue-therapie-fur-primar-biliare-cholangitis-pbc-seit-fast-einem-jahrzehnt\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ipsen.com\/germany\/press-releases\/ipsen-erhalt-eu-zulassung-fur-iqirvo-elafibranor-als-erste-neue-therapie-fur-primar-biliare-cholangitis-pbc-seit-fast-einem-jahrzehnt\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.ipsen.com\/germany\/press-releases\/ipsen-erhalt-eu-zulassung-fur-iqirvo-elafibranor-als-erste-neue-therapie-fur-primar-biliare-cholangitis-pbc-seit-fast-einem-jahrzehnt\/#primaryimage","url":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/6\/2023\/12\/06080352\/PR-final.jpg","contentUrl":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/6\/2023\/12\/06080352\/PR-final.jpg","width":856,"height":446},{"@type":"BreadcrumbList","@id":"https:\/\/www.ipsen.com\/germany\/press-releases\/ipsen-erhalt-eu-zulassung-fur-iqirvo-elafibranor-als-erste-neue-therapie-fur-primar-biliare-cholangitis-pbc-seit-fast-einem-jahrzehnt\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ipsen.com\/germany\/"},{"@type":"ListItem","position":2,"name":"Ipsen erh\u00e4lt EU-Zulassung f\u00fcr IQIRVO\u00ae (Elafibranor) als erste neue Therapie f\u00fcr prim\u00e4r bili\u00e4re Cholangitis (PBC) seit fast einem Jahrzehnt"}]},{"@type":"WebSite","@id":"https:\/\/www.ipsen.com\/germany\/#website","url":"https:\/\/www.ipsen.com\/germany\/","name":"Germany","description":"","publisher":{"@id":"https:\/\/www.ipsen.com\/germany\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ipsen.com\/germany\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"de"},{"@type":"Organization","@id":"https:\/\/www.ipsen.com\/germany\/#organization","name":"Germany","url":"https:\/\/www.ipsen.com\/germany\/","logo":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.ipsen.com\/germany\/#\/schema\/logo\/image\/","url":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/6\/2023\/12\/07165742\/Latest_Ipsen-logo_168x48.svg","contentUrl":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/6\/2023\/12\/07165742\/Latest_Ipsen-logo_168x48.svg","caption":"Germany"},"image":{"@id":"https:\/\/www.ipsen.com\/germany\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.ipsen.com\/germany\/wp-json\/wp\/v2\/press_release\/2320","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipsen.com\/germany\/wp-json\/wp\/v2\/press_release"}],"about":[{"href":"https:\/\/www.ipsen.com\/germany\/wp-json\/wp\/v2\/types\/press_release"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/germany\/wp-json\/wp\/v2\/users\/9"}],"version-history":[{"count":2,"href":"https:\/\/www.ipsen.com\/germany\/wp-json\/wp\/v2\/press_release\/2320\/revisions"}],"predecessor-version":[{"id":2324,"href":"https:\/\/www.ipsen.com\/germany\/wp-json\/wp\/v2\/press_release\/2320\/revisions\/2324"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/germany\/wp-json\/wp\/v2\/media\/537"}],"wp:attachment":[{"href":"https:\/\/www.ipsen.com\/germany\/wp-json\/wp\/v2\/media?parent=2320"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipsen.com\/germany\/wp-json\/wp\/v2\/categories?post=2320"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipsen.com\/germany\/wp-json\/wp\/v2\/tags?post=2320"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}